Top Stock Gainers
Explore the biggest stock gainers today along with up-to-date performance data, including the latest price, share price changes, trading volume, and more. We cover the top stock gainers every day with market data, news, and analysis from our Foolish experts.
Related Articles
Featured Article
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
Cory Renauer
|
Jun 28, 2025
2 Beaten-Down Stocks to Avoid
Prosper Junior Bakiny
|
Jun 27, 2025
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Eric Volkman
|
May 9, 2024
The company has great potential if and when it enters the commercial stage.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
Alex Carchidi
|
Mar 7, 2024
The company now has a chance to get its lead program out the door a bit sooner.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Prosper Junior Bakiny
|
Mar 4, 2024
The biotech has bounced back some in the past year.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Danny Vena
|
Mar 2, 2024
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
2 Under-the-Radar Stocks With Incredible Upside Potential
Prosper Junior Bakiny
|
Jan 28, 2024
It's also important to consider their downsides.
Could Editas Medicine Become the Next CRISPR Therapeutics?
Alex Carchidi
|
Jan 21, 2024
The similarities between the pair are striking, but it might not be enough.
View More Articles